Abbreviations

ER: Endoplasmic Reticulum; TNF-α: Tumour Necrosis Factor Alpha; IL-6: Interleukin 6; IL-1β: Interleukin 1 Beta; NAFLD: Non-Alcoholic Fatty Liver Disease; NASH: Non-Alcoholic Steatohepatitis; NLRP3: NOD-, LRR- and Pyrin Domain-Containing Protein 3; MCD: Methionine Choline Deficient; TG: Triglyceride

References

1. Diseases, N.I.o.D.a.D.a.K. Nonalcoholic fatty liver disease and NASH (2020).
2. Chalasani N., et al. “The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases”. Hepatology1 (2018): 328-357.
3. Wree A., et al. “NLRP3 inflammasome activation is required for fibrosis development in NAFLD”. Journal of Molecular Medicine10 (2014): 1069-1082.
4. Henao-Mejia J., et al. “Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity”. Nature7384 (2012): 179-185.
5. Mridha AR., et al. “NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice”. Journal of Hepatology5 (2017): 1037-1046.
6. Parthasarathy G., et al. “Pathogenesis of Nonalcoholic Steatohepatitis: An Overview”. Hepatology Communications4 (2020): 478-492.

Citation

Citation: Ali Mahzari. “Non-Alcoholic Steatohepatitis (NASH): A Critical Stage of Chronic Liver Disease". Acta Scientific Gastrointestinal Disorders 3.9 (2020): 14-15.

Copyright

Copyright: © 2020 Ali Mahzari. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.